JP2005531281A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005531281A5 JP2005531281A5 JP2003542564A JP2003542564A JP2005531281A5 JP 2005531281 A5 JP2005531281 A5 JP 2005531281A5 JP 2003542564 A JP2003542564 A JP 2003542564A JP 2003542564 A JP2003542564 A JP 2003542564A JP 2005531281 A5 JP2005531281 A5 JP 2005531281A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- gene
- lung cancer
- level
- characteristic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims 153
- 230000014509 gene expression Effects 0.000 claims 123
- 238000000034 method Methods 0.000 claims 86
- 208000020816 lung neoplasm Diseases 0.000 claims 74
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 72
- 201000005202 lung cancer Diseases 0.000 claims 72
- 239000000203 mixture Substances 0.000 claims 43
- 210000004027 cell Anatomy 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 150000007523 nucleic acids Chemical class 0.000 claims 35
- 239000003814 drug Substances 0.000 claims 24
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 229940124597 therapeutic agent Drugs 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 229920001184 polypeptide Chemical class 0.000 claims 18
- 239000007787 solid Substances 0.000 claims 17
- 238000011282 treatment Methods 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 238000004590 computer program Methods 0.000 claims 10
- 210000005265 lung cell Anatomy 0.000 claims 10
- 208000009956 adenocarcinoma Diseases 0.000 claims 9
- 238000001514 detection method Methods 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 101150056950 Ntrk2 gene Proteins 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000004952 protein activity Effects 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000000159 protein binding assay Methods 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 238000001308 synthesis method Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 230000002113 chemopreventative effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000005462 in vivo assay Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 239000013610 patient sample Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33629801P | 2001-11-02 | 2001-11-02 | |
| US33531701P | 2001-11-02 | 2001-11-02 | |
| US33602401P | 2001-11-02 | 2001-11-02 | |
| PCT/US2002/035149 WO2003040317A2 (en) | 2001-11-02 | 2002-11-02 | Lung cancer therapeutics and diagnostics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005531281A JP2005531281A (ja) | 2005-10-20 |
| JP2005531281A5 true JP2005531281A5 (https=) | 2006-01-05 |
Family
ID=27407051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003542564A Pending JP2005531281A (ja) | 2001-11-02 | 2002-11-02 | 肺癌の治療および診断 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030219768A1 (https=) |
| EP (1) | EP1520032A4 (https=) |
| JP (1) | JP2005531281A (https=) |
| AU (1) | AU2002353972A1 (https=) |
| WO (1) | WO2003040317A2 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1606305A4 (en) * | 2003-03-12 | 2009-06-24 | Vasgene Therapeutics Inc | NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH |
| CA2527680A1 (en) * | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor |
| US20070270504A1 (en) * | 2003-06-20 | 2007-11-22 | Avalon Pharmaceuticals, Inc. | Identification of Therapeutic Agents Using Genetic Fingerprinting |
| WO2005032495A2 (en) * | 2003-10-03 | 2005-04-14 | Bayer Pharmaceuticals Corporation | Gene expression profiles and methods of use |
| CA2540280A1 (en) * | 2003-10-07 | 2005-04-21 | Entelos, Inc. | Simulating patient-specific outcomes |
| US20060088862A1 (en) * | 2004-09-30 | 2006-04-27 | Nancy Lee | Drug screening and molecular diagnostic test for early detection of colorectal cancer: reagents, methods, and kits thereof |
| JP4580206B2 (ja) * | 2004-10-08 | 2010-11-10 | 新日鉄ソリューションズ株式会社 | 化合物推定装置、化合物推定方法及びそのプログラム |
| EP1806581A4 (en) * | 2004-10-28 | 2011-08-17 | Seems Inc | DISEASE DIAGNOSTIC SYSTEM |
| EP1829967A4 (en) * | 2004-12-03 | 2008-04-23 | Aichi Prefecture | METHOD FOR DIAGNOSIS OF MALIGNEM LYMPHOMA AND ASSESSMENT OF THE FORECASTING THEREOF |
| EP3211093A1 (en) * | 2005-04-14 | 2017-08-30 | The Trustees of Boston University | Diagnostic for lung disorders using class prediction |
| WO2007103541A2 (en) | 2006-03-09 | 2007-09-13 | The Trustees Of Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
| WO2008039071A2 (en) * | 2006-09-29 | 2008-04-03 | Agendia B.V. | High-throughput diagnostic testing using arrays |
| WO2009039190A1 (en) | 2007-09-17 | 2009-03-26 | Gene Express, Inc. | Cancer risk biomarker |
| WO2009123990A1 (en) * | 2008-03-31 | 2009-10-08 | The University Of Toledo | Cancer risk biomarker |
| US8652798B2 (en) * | 2008-05-20 | 2014-02-18 | The Regents Of The University Of California | Analysis of ex vivo cells for disease state detection and therapeutic agent selection and monitoring |
| WO2010011642A2 (en) * | 2008-07-21 | 2010-01-28 | The Trustees Of The University Of Pennsylvania | Methods and compositions using splicing regulatory proteins involved in tumor suppression |
| AU2011316986A1 (en) * | 2010-10-20 | 2013-06-06 | Rush University Medical Center | Lung cancer tests |
| US9687467B2 (en) | 2011-04-04 | 2017-06-27 | Children's Medical Center Corporation | Diagnosis and treatment of taxane-resistant cancers |
| US10338073B2 (en) | 2011-04-14 | 2019-07-02 | Raymond U. Osarogiagbon | Lymph node specimen collection kit and method of pathological analysis for lung cancer diagnosis using such a kit |
| US9753037B2 (en) | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| EP3080299B1 (en) | 2013-12-09 | 2020-09-30 | Rush University Medical Center | Biomarkers of rapid progression in advanced non-small cell lung cancer |
| WO2017197335A1 (en) | 2016-05-12 | 2017-11-16 | Trustees Of Boston University | Nasal epithelium gene expression signature and classifier for the prediction of lung cancer |
| CN110574414B (zh) | 2016-12-27 | 2023-04-04 | 株式会社电装 | 用于微定位传感器通信的系统和方法 |
| WO2021158713A1 (en) * | 2020-02-03 | 2021-08-12 | Tdl Innovations Llc | Foam compositions for the treatment of cancer |
| CN118969273B (zh) * | 2024-07-25 | 2025-02-28 | 常州贝格尔医学检验实验室有限公司 | 一种靶向用药方案的评价方法及系统 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002509707A (ja) * | 1998-03-31 | 2002-04-02 | ジェンザイム・コーポレーション | 肺腫瘍細胞を同定するための組成物および方法 |
| AU4651500A (en) * | 1999-04-23 | 2000-11-10 | Corixa Corporation | Compositions and methods for therapy and diagnosis of head/neck and lung squamous cell carcinoma |
| EP1242598A2 (en) * | 1999-12-30 | 2002-09-25 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
| WO2001060860A2 (en) * | 2000-02-17 | 2001-08-23 | Millennium Predictive Medicine, Inc. | Genes differentially expressed in human prostate cancer and their use |
-
2002
- 2002-11-02 AU AU2002353972A patent/AU2002353972A1/en not_active Abandoned
- 2002-11-02 JP JP2003542564A patent/JP2005531281A/ja active Pending
- 2002-11-02 US US10/286,989 patent/US20030219768A1/en not_active Abandoned
- 2002-11-02 WO PCT/US2002/035149 patent/WO2003040317A2/en not_active Ceased
- 2002-11-02 EP EP02789376A patent/EP1520032A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005531281A5 (https=) | ||
| KR102622307B1 (ko) | 후성유전적 염색체 상호작용 | |
| JP2007506426A5 (https=) | ||
| JP2005500039A5 (https=) | ||
| JPH09508800A (ja) | 差次的発現遺伝子の同定法 | |
| JP2009543552A5 (https=) | ||
| JP2005503779A (ja) | 致死性の高い癌の分子シグネチャー | |
| EA020795B1 (ru) | Генетические маркеры, ассоциированные с ответом на интерферон-альфа | |
| KR20080063343A (ko) | 비인강 암종에서의 예후 서브클래스의 확인을 위한 유전자발현 프로파일링 | |
| CN111876478B (zh) | 肺结节诊断标志物及应用 | |
| JP2003508022A5 (https=) | ||
| KR20090027735A (ko) | Ｔａｋ1 억제제를 사용한 암 치료 방법 | |
| JP2008512984A5 (https=) | ||
| JP2019503176A5 (https=) | ||
| JP2005323573A (ja) | 遺伝子発現データ解析方法および、疾患マーカー遺伝子の選抜法とその利用 | |
| JP2003524017A5 (https=) | ||
| JP2008514209A5 (https=) | ||
| JP4245539B2 (ja) | 糖尿病の特異的マーカー | |
| WO2018150513A1 (ja) | 物質の遺伝毒性の評価方法 | |
| JP2020522501A (ja) | Ｔ−ｄｍ１による癌治療成績の予測方法 | |
| US20160267244A1 (en) | Methods of predicting cancer lethality using replikin counts | |
| EP3676404B1 (en) | Methods of selecting a treatment for breast cancer patients | |
| EP1427858A2 (en) | Specific markers for multiple sclerosis | |
| US20030194701A1 (en) | Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis | |
| EP0290144A1 (en) | Method of detecting incipient resistance to therapeutic agents in cancer patients |